DEPARTMENT OF MEDICAL ONCOLOGY
The department of medical oncology is responsible for diagnosing and treating all cases of hematological malignancies as well as giving chemotherapy to majority of the solid tumors in various settings. The Department of Medical Oncology is committed to improving the diagnosis and treatment of adult patients with cancer. To meet this mission there is a broad range of basic research, clinical research, patient care, and teaching.
The consultants of this department are qualified and highly experienced. Their efforts by commitimg themselves to patient care has resulted in improved survival rates and reduced morbidity. The department practices high dose rate chemotherapy, day care chemotherapy etc. The nursing staff as well as the junior doctors are well versed in caring for patients with long term venous access devices and implantable ports.
The department of medical oncology consists of 6faculty members and post graduate students. The department runs outpatient clinic services every day, about 150-200 patients visit the OPD per day. At a time around 50 inpatients are admitted for chemotherapy, management of complications and for work up.
For every new patient, after diagnosis is established, there is departmental meeting for planning of treatment. Department has its own medical minor OT where all minor procedures such as Bone marrow aspiration/ biopsy, ascitic and pleural tapping, trucut biopsies etc are carried out under full aseptic precautions.
The department also provides facility for autologous stem cell transplant for malignancies like NHL, HL, and multiple myeloma.
The academic activities of the department include.
1. Long seminars on every Tuesdays
2. Short seminar on every Wednesdays
3. Case presentations on every Saturdays
4. Multi disciplinary seminars on every Fridays.
The department provides prestigious DM degree in Medical Oncology. Every year 2 candidates are selected by all India wise entrance examination conducted by the Rajiv Gandhi University. Out of this one seat is reserved for in service candidates. Course is of 3years duration. Exams are held in month of June or July. The exams are conducted in two parts. First part comprise of written exam containing 90 marks. Paper contains 90 multiple choice questions. Around 5 candidates are selected on the basis of merit list of this theory exam. Second part comprise of interview of 10 marks. Final merit list is made by adding both theory and interview marks. Candidates are selected on the basis of final merit list.
During the course student is exposed to all kinds of treatment for all solid tumors and hematological malignancies. Apart from this they have speciality posting during which they are posted in paediaric oncology, hematology and various other oncology departments.
MD medicine students from various medical colleges in Karnataka are getting training in oncology during their special posting in KMIO.
1. Dr. K.C.Lakshmaiah- Prof. and H.O.D
M.B.B.S., M.D., D.M
2. Dr. T.M.Suresh-Professor
M.B.B.S., M.D., D.M
3. Dr. Rani Acharya- Associate Professor
M.B.B.S., M M.D.,
4. Dr. Loknath-Associate Professor
M.B.B.S., M.D., D.M
5. Dr. Govind Babu- Associate Professor
6. Dr. Linu Jacob-Assistant Professor
M.B.B.S., M.D., D.M
1. Dr. Ankit Jain
2. Dr. Sajeevan K.V.
3. Dr. Satish C.T.
4. Dr. Tejinder Singh
5. Dr. Rajeev LK.
6. Dr. Mukul Goyal
The department is involved in conducting many multicentric clinical trials. The department has team of experts involved in clinical trials. Medical Oncology dept, at Kidwai is among the few prestigious departments experienced in conducting phase I clinical trials.
The ongoing clinical research projects are.
1. Title: "A Phase 3, Multicentre, Randomized, Placebo- Controlled, Double- BlindTrial of AMG 706 in combination with Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer" Protocol No:20050201
2. A Phase 2, Muilticenter, open label, Randomised, Trial of AMG 706 or Bevacizumab in combination with Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer" Protocol No.20060136.
3. A Randomized, 4-arm, placebo-controlled phase 2 trial of AMG 386 in combination with bevacizumab and paclitaxel as first line chemotherapy in subjects with Her2-negative, metastatic or locally recurrent breast cancer-Protocol no.(amg386)20060341
4. A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of paclitaxel in combination with AMG 386 in subjects with Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer-Protocol no (AMG386)20060342
5. A randomized open-label, multicenter, phase 3 study, phase 3 study of epoetin alfa plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer receiving standard chemotherapy.
6. A multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thrombo embolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemo therapy. Protocol: EFC 6521
7. An open label, randomized multicentric clinical trial of Mycobacterium w in combination with Docetaxel versus Docetaxel in metastatic Harmone Refractory Prostrate Cancer
8. A Randomized Blind, Multicenter study of Denosumab Compared withZolendronic Acid (Zometa @) in the treatment of bone Metastasis in Subjects with Advanced Breast Cancer (AMGEN Study Denosumab-20050136)
9. A Multinational Randomized, Double Blind study comparing Aflibercept versus placebo in patients treated with second-line Docetaxel after failure of one platinum based therapy, for locally advanced or Metastatic Non -small cell Lung Cancer (NSCLC)
10. Open Lable, Randomized, Comparative Multicenter Study to Assess Safety and Efficacy of BIOMAb-EGFR (Nimotuzumab) in Combination with Chemotherapy Versus Chemotherapy alone in the treatment of Patient with stage III/IV Non Small Cell Lung (NSCLC).
11. A Randomized phase III study of Pemetrexed in combination with CisplatinVersus Cisplatin Monotherapy in patients with Recurrent or etastatic Head and Neck Cencer.
12. A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera@) after induction of response with chemotherapy plus Rituxmab in comparison with no maintenance therapy.
13. Active implementation of Quality of Life (QOL)assessment in clinical practice for patients with advanced NSCLC and comparison of QOL and response points
14. Phase III Study of Vinfluine plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients with unresectable, locally recurrent or Metastatic Breast Cancer after prior Anthracycline-based Adjuvant Chemotherapy” – Protocol No.l.00070IN 303 BO-3408.
15. An Open label dose finding Prospective multi center randomized parallel-group to Assess the Efficacy safety of three different dose levels of AVI-014(GCSF) compared with the standard dose of neupogen in breast cancer patient at high (>20%)risk for Chemotherapy-Induced Severe Neutropenia” enrollment closed,only follow up.
16. A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel andCarboplatin in patients with Previously Untreated Locally Advanced or Metastatic Non-Small –Cell Lung Cancer. Enrollment closed, only follow up.
17. A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC followed by Lxabepilone Compared to Sequential AC followed by Paclitaxel in women with early stage breast cancer.
18. A Phase III, Randomized , placebo-controlled,Double-Blind Study to Assess the Efficacy and Safety of One-daily orally Administered ZD4054 10 mg in Non metastatic Hormone-resistant Prostate Cancer Patients.
19. A Randomized, Double-blind, Multicentre Phase ll / lll Study to Compare the efficacy of Cediranib (RECENTIN)TM, AZD2171) in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FolFox), to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with previously Untreated Metastatic Colerectal Cancer.
20. A Phase1/2, Modified Dose Escalation, Opan Label Trial to Determine the
Therapeutic Effect and safety of INCBOO7839 Combined with Trastuzumab in
Patients with previously untreated HER2 positive Metastatic Breast Cancer
The following abstracts were accepted and published in ASCO 2008 annual meeting:
Category: Head and Neck Cancer – The efficacy, toxicity profile and tolerability of
Cisplatin plus 5-FU versus docetaxel plus carboplatin as induction therapy in locally
Advanced oral cancer: An experience from a tertiary cancer centre from South India.
Abstract – N0. 17017
Category: Supportive Care – Use of long term venous access in cancer patiens:
Experience from a tertiary cancer centre in South India. Abstract- N0.20710.
Category: Chronic Myeloid Leukemia – Dose escalation of imatinib in CML, patients with
Sub-optimal response to conventional dosage: I s it worth it? Abstract-N0.18026.Abstract published at first European lung cancer conference 2008:
Pharmacocconomic study of etoposide and cisplatin compared withy paclitaxel cisplatin in
nonsmall lung cancer a study in Indian population.
Publication in annual conference of Clinical Oncology Society of Australia (COSA-2008):
Retrospective analysis of incidences of visceral and non-visceral metastasis in triple
negative and non-triple negative breast cancer patient-Experience from a tertiary care
Centre from South India.